SCHEMBL3669203

SCHEMBL3669203

O=C(c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1)N(CCO)Cc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 11/20 0.74
ROCK2 O75116 11/20 0.74
GSK3B P49841 10/20 0.74
PRKACA P17612 9/20 0.74
CDK2 P24941 9/20 0.74
ROCK1 Q13464 9/20 0.74
AURKB Q96GD4 9/20 0.74
CDK5 Q00535 9/20 0.74
DYRK1A Q13627 9/20 0.74
CDK1 P06493 8/20 0.74
GSK3A P49840 8/20 0.74
PRKCD Q05655 8/20 0.74
CDC42BPA Q5VT25 8/20 0.74
CLK4 Q9HAZ1 8/20 0.74
AURKA O14965 7/20 0.74
AKT1 P31749 7/20 0.74
PRKAA1 Q13131 7/20 0.74
MKNK2 Q9HBH9 7/20 0.74
RPS6KA3 P51812 7/20 0.74
PLK4 O00444 7/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3632798 0.91 ROCK2 (0.74) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3668029 0.90 CDC7 (0.78) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3665661 0.85 GSK3B (1.00) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3667213 0.84 GSK3B (0.79) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3673480 0.83 ROCK2 (0.82) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3670360 0.83 GSK3B (0.84) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3668848 0.82 GSK3B (1.00) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3639411 0.81 ROCK2 (0.80) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3667241 0.81 CDC7 (0.75) CDC7ROCK2GSK3BPRKACACDK2
SCHEMBL3668339 0.81 ROCK2 (1.00) CDC7ROCK2GSK3BPRKACACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885GSK3B 1/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885ROCK2 48/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.